U.S. FDA backs COVID-19 booster shots tailored to target Omicron BA.4, BA.5 subvariants

Source: globalnews.ca : 2022-06-30 15:44:03 :

The U.S. Food and Drug Administration on Thursday recommended booster doses of COVID-19 vaccines be modified beginning this fall to include components tailored to combat the currently dominant Omicron BA.4 and BA.5 subvariants of the coronavirus.

The FDA said manufacturers would not need to change the vaccine for the primary vaccination series, saying the coming year will be “a transitional period when this modified booster vaccine may be introduced.”

The new booster shots would be bivalent vaccines, meaning doses would target both the original virus as well as the Omicron subvariants.

Read more:

COVID-19 boosters recommended this fall ahead of future pandemic wave: NACI

The decision follows a recommendation by the agency’s outside advisers to change the design of the shots this fall in order to combat more prevalent versions of the coronavirus.

Story continues below advertisement

BA.4 and BA.5 are now estimated to account for more than 50% of U.S. infections, according the U.S. Centers for Disease Control and Prevention, and have also become dominant elsewhere.

The FDA said in a statement on Thursday that it hoped the modified vaccines could be used in early to mid-fall.

Pfizer Inc PFE.N with partner BioNTech SE 22UAy.DE and Moderna Inc MRNA.O have been testing versions of their vaccines modified to combat the BA.1 Omicron variant that caused the massive surge in cases last winter.


Click to play video: '2 new Omicron sub-variants discovered as COVID-19 cases continue to decline globally: WHO'







2 new Omicron sub-variants discovered as COVID-19 cases continue to decline globally: WHO


2 new Omicron sub-variants discovered as COVID-19 cases continue to decline globally: WHO – May 4, 2022

Although they have said those vaccines worked against BA.1 and the more recently circulating variants, they did see a lower immune response against BA.4 and BA.5.

The companies had already been manufacturing their BA.1 vaccines, and said on Tuesday that swapping to a BA.4/BA.5 version could slow the rollout.

Story continues below advertisement

Pfizer/BioNTech, which on Wednesday announced a $3.2 billion contract to supply more COVID vaccine doses to the United States, said they would have a substantial amount of BA.4/BA.5 vaccine ready for distribution by the first week of October.

Moderna said it would be late October or early November before it would have the newly modified vaccine ready.

U.S. FDA advisers recommend change to COVID vaccine composition for fall.

— Reporting by Michael Erman in New Jersey and Leroy Leo in Bengaluru

© 2022 The Canadian Press



Read the original article on Here!

Leave a Reply

Your email address will not be published.